Çã±ÔÇÏ ¸íÀÇ

¸ðµç ȯÀÚ¸¦ ³ªÀÇ °¡Á·Ã³·³ ÃÖ¼±À» ´ÙÇØ Áø·áÇϰڽÀ´Ï´Ù

Çã±ÔÇÏ ¸íÀÇ

  • ¼Ò ¼Ó
    ¿¬¼¼´ë¼¼ºê¶õ½ºº´¿ø
  • Áø·á°ú
    À̽Ŀܰú
  • Àü¹®ºÐ¾ß
    Àå±âÀ̽Ä(½ÅÀå), Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀ̽Ä, °í°¨ÀÛ È¯ÀÚ ½ÅÀåÀ̽Ä, ·Îº¿ ½ÅÀå À̽Ä

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¿¬¼¼´ë ÀÇ´ë Çлç
  • ¿¬¼¼´ë ÀÇ´ë ¼®»ç
  • ¿¬¼¼´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼¼ºê¶õ½ºº´¿ø Àå±âÀ̽ļ¾ÅÍ ¼ÒÀå
  • úÞ) ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¿Ü°úÇб³½Ç ±³¼ö
  • ¼¼ºê¶õ½ºº´¿ø À̽ĿܰúÀå (2019~2025)
  • ÇØ¿Ü¿¬¼ö (¹Ì±¹ ÇϹöµåÀÇ´ë Massachusetts General Hospital) (2015~2017)

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѿܰúÇÐȸ Á¤È¸¿ø
  • ´ëÇÑÀ̽ÄÇÐȸ Á¤È¸¿ø
  • The Transplantation Society Á¤È¸¿ø
  • American Society of Transplantation Á¤È¸¿ø
  • ´ëÇѽÅÃéÀåÀ̽Ŀܰú¿¬±¸È¸ Á¤È¸¿ø (ÇмúÀ§¿øÀå)
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Longitudinal Changes in Left Ventricular Geometry After Kidney Transplantation and Their Implications on Cardiovascular Risk
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö KIDNEY MEDICINE
Á¦ ¸ñ Bisphosphonates as a Tacrolimus-Sparing Strategy in Kidney Transplantation: Insights from a Retrospective Analysis
¹ßÇ¥³âµµ 2026 ¹ßÇ¥Áö YONSEI MEDICAL JOURNAL
Á¦ ¸ñ Cytomegalovirus Infection in Seropositive Kidney Transplant Recipients With Diverse Immunological Risks Under Preemptive Strategy
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö JOURNAL OF MEDICAL VIROLOGY
Á¦ ¸ñ Effects of the pretransplant obesity on kidney transplant outcomes in Korea: a nationwide cohort study
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö BMC NEPHROLOGY
Á¦ ¸ñ Clinical implications of early blood transfusion after kidney transplantation
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö SCIENTIFIC REPORTS
Á¦ ¸ñ Optimum tacrolimus trough levels for enhanced graft survival and safety in kidney transplantation: a retrospective multicenter real-world evidence study
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö INTERNATIONAL JOURNAL OF SURGERY
Á¦ ¸ñ Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö FRONTIERS IN IMMUNOLOGY

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¿¬¼¼´ë¼¼ºê¶õ½ºº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1599-1004

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¿¬¼¼´ë¼¼ºê¶õ½ºº´¿øÀº 1885³â H.N.¾Ë·»ÀÌ ¼¼¿î ¿ì¸®³ª¶ó ÃÖÃÊÀÇ ¼­¾ç½Ä º´¿øÀÎ Á¦Áß¿ø(±¤Çý¿ø)À¸·Î ⸳µÈ ÀÌ·¡ 130³â µ¿¾È ÃÖ°íÀÇ Ã·´Ü ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀÌ´Ù. ±¹³» ÃÖÃÊ·Î Áø·áÀÇ Àü¹®È­¸¦ ÅëÇÑ ÀÇ·áÀÇ Áú Çâ»óÀ» À§ÇØ ÀçȰº´¿ø, ½ÉÀåÇ÷°üº´¿ø, ¾È.À̺ñÀÎÈİúº´¿ø, ¾î¸°À̺´¿ø°ú ÀÀ±ÞÁø·á¼¾ÅÍ, ±¹Á¦Áø·á¼¾ÅÍ µî Àü¹®¼¾ÅÍ, ¾ÏÀü¹®Å¬¸®´ÐÀ» ¿î¿µÇϰí ÀÖ´Ù.

¿¬¼¼´ë¼¼ºê¶õ½ºº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼­´ë¹®±¸ ¿¬¼¼·Î 50-1

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä